Serum Institute of India plans to launch another Covid-19 vaccine in India by June

SII-Pune-e1612173090517.jpg

Pune-based Serum Institute of India (SII) is the producer of the Oxford-AstraZeneca Covishield vaccine in India. (Image Source: Serum Institute of India)

Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said that the company hopes to launch the Covid-19 vaccine in partnership with US-based biotech company Novavax called Covovax in India by June 2021. Poonawalla tweeted: “Our partnership for a Covid-19 vaccine with Novavax has published excellent efficacy results. We have applied to start trials in India.” 

A day before the announcement, Novavax Inc announced that according to a preliminary analysis conducted in the UK, its vaccine was 89.3% effective in preventing Covid-19 and was nearly as effective in protecting against the new variant first discovered in the UK and South Africa. 

In September 2020, SII tied-up with Novavax Inc to manufacture one billion doses of the vaccine in 2021. The supply and license agreement with Novavax allows SII to manufacture and commercialize Novavax’s vaccine. Novavax’s Covid-19 vaccine is protein-based. 

Covovax will be the second Covid-19 vaccine from SII and the third Covid-19 vaccine for India. SII is the producer of the Oxford-AstraZeneca Covishield vaccine in India.  

Also Read: In future more made-in-India vaccines to come, says PM Modi

Also Read: India gifts 500,000 vaccines to Sri Lanka

Leave a Reply

Your email address will not be published. Required fields are marked *

scroll to top